ArticlePakistan journal of medical sciences2026
CD56-Positive Acute Myeloid Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: A case report and narrative review.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, there are no reported cases of CD56+ acute myeloid leukemia (AML) combined with hemophagocytic lymphohistiocytosis (HLH). Meanwhile, there is no standardized treatment plan for AML combined with HLH. This article reports a 27 years old female patient with CD56+ AML who received treatment with an HLH-94-based regimen combined with B cell lymphoma 2 (BCL-2) inhibitor venetoclax. After treatment, the patient's body temperature returned to normal and laboratory parameters related to HLH improved. Two weeks after chemotherapy, bone marrow reassessment showed 3% blast cells and undetectable MLL-AF9 fusion transcripts; complete remission was subsequently documented on May 23, 2024. To our knowledge, this represents a rarely reported case of CD56+AML with HLH. The result suggests that BCL-2 targeted therapy combined with HLH-94 regimen may be a safe and promising strategy for treating CD56+AML with HLH, and may provide a basis for the selection of treatment strategies for such patients in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.